PROCEPT Biorobotics Corp (PRCT) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. PROCEPT Biorobotics is a surgical robotics company focused on urology, specifically treating benign prostatic hyperplasia (BPH) with its AquaBeam and HYDROS Robotic Systems. As of the reporting date, the company had a global install base of 572 robotic systems (445 in the U.S.).
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $58.4 million | $35.1 million | $156.3 million | $92.6 million |
| Gross Profit | $36.9 million | $18.9 million | $93.4 million | $49.8 million |
| Gross Margin | 63% | 54% | 60% | 54% |
| Net Loss | $(21.0) million | $(24.6) million | $(72.6) million | $(78.4) million |
| Net Loss Per Share | $(0.40) | $(0.51) | $(1.41) | $(1.70) |
| Cash & Equivalents | $196.8 million (as of Sept 30, 2024) | |||
| Long-Term Debt | $51.4 million (Principal $52.0 million) | |||
| Operating Cash Flow (9M) | $(66.8) million used |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 66% year-over-year in Q3 and 69% for the nine-month period. Growth was driven by higher sales volumes of systems, handpieces, and service contracts, with U.S. revenue accounting for 89% of total Q3 revenue.
- Margin Expansion: Gross margin improved to 63% in Q3 (from 54% in Q3 2023) due to increased unit sales spreading fixed manufacturing overhead and higher average selling prices.
- Expense Increases: Operating expenses rose 33% in Q3. R&D expenses increased 44% due to product development and tooling, while SG&A increased 30% driven by commercial expansion and stock-based compensation.
- Loss Reduction: Net loss narrowed by 15% in Q3 and 7% for the nine-month period compared to the prior year, despite higher operating expenses, due to significant revenue growth and increased interest income.
Guidance, Outlook, and Risks
- Product Launch: The company received FDA 510(k) clearance for the next-generation HYDROS Robotic System on August 20, 2024. It features AI assistance (FirstAssist AI) and integrated ultrasound. The company will continue selling the AquaBeam system in the U.S. through Q4 2024 to manage the transition.
- Clinical Trials: On October 7, 2024, the FDA approved a pivotal IDE clinical trial (WATER IV PCa) comparing Aquablation therapy to radical prostatectomy for localized prostate cancer. The company also received Breakthrough Device Designation for this indication.
- Liquidity: Management believes existing cash ($196.8 million) and anticipated revenue are sufficient to fund operations for at least the next 12 months. The company has a $52.0 million term loan maturing in October 2027, currently in an interest-only period.
- Risks: Key risks include the pace of market adoption, reimbursement decisions by third-party payors, supply chain disruptions, and the success of ongoing clinical trials. The company is exposed to interest rate fluctuations on its variable-rate debt.
Investor Verification Checklist
- Verify the adoption rate and utilization metrics of the new HYDROS Robotic System following its August 2024 launch.
- Monitor progress and enrollment rates of the WATER IV PCa clinical trial for prostate cancer indications.
- Review the trajectory of gross margins as the company scales production and transitions product mix.
- Assess the impact of the $52.0 million debt covenant requirements (minimum unrestricted cash or revenue growth) as the company approaches the end of its interest-only period.
- Track the expansion of the U.S. install base beyond the current 445 systems to validate revenue growth sustainability.